- Market Capitalization, $K 12,057,778
- Shares Outstanding, K 1,092,190
- Annual Sales, $ 16,659 M
- Annual Income, $ -3,990 M
- 60-Month Beta 1.50
- Price/Sales 0.72
- Price/Cash Flow 2.82
- Price/Book 1.09
|Period||Period Low||Period High||Performance|
| || |
-0.03 (-0.28%)since 03/12/21
| || |
-0.79 (-6.84%)since 01/13/21
| || |
+0.43 (+4.16%)since 04/13/20
New York, US, The business report released by Zion Market Research on market is focused to facilitate a deep understanding of the market definition, potential, and scope. The report is curated after deep...
Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the first quarter on Wednesday, April 28, 2021 at 7:00 a.m. ET....
Teva Canada Amplifies Commitment to Canadian Caregivers - Introduces new resources to support and improve mental health of Caregivers
--April 6, 2021 - National Caregiver Day Event - 12:00 PM EDT
The global hormonal contraceptives market size is expected to showcase considerable growth by reaching USD 24,330.1 million by 2027 while exhibiting a CAGR of 5.4% between 2020 and 2027.
The latest research report on delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and...
The global central nervous system treatment market size is expected to reach USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast period. The surge in chronic neurological illness...
Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.
|Teva Pharmaceutical Industries Ltd|
|Pharmaceutical Vaneck ETF|
|GS Activebeta International ETF|
|GS Innovate Equity ETF|
|FTSE RAFI Dev Markets Ex-U.S. Invesco ETF|
|Db-Xt MSCI EM Mkts Hgd Eq|
|3rd Resistance Point||11.10|
|2nd Resistance Point||11.02|
|1st Resistance Point||10.89|
|1st Support Level||10.68|
|2nd Support Level||10.60|
|3rd Support Level||10.47|